Tesamorelin vs MK-677
Both Tesamorelin and MK-677 are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
Tesamorelin
Evidence ATesamorelin (Egrifta)
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
View full Tesamorelin profile →MK-677
Evidence B+Ibutamoren (MK-677)
An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.
View full MK-677 profile →Side-by-Side
| Attribute | Tesamorelin | MK-677 |
|---|---|---|
| Evidence Grade | A | B+ |
| FDA Status | FDA-approved for HIV-associated lipodystrophy | Not FDA-approved — investigational (orally active GH secretagogue) |
| Typical Dose | 2 mg daily (subcutaneous) | 10–25 mg orally, once daily |
| Clinics Indexed | 178 | 165 |
| Categories | growth-hormone, fat-loss | growth-hormone, anti-aging |
Key reported benefits — Tesamorelin
- ✓Visceral fat reduction
- ✓Natural GH stimulation
- ✓Cognitive benefit
- ✓Lean mass
Key reported benefits — MK-677
- ✓Sustained GH/IGF-1 elevation
- ✓Sleep depth
- ✓Lean mass
- ✓Bone density
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.